+ Watch CYCC
on My Watchlist
A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
With the dilutive financing today, all the pieces are in place for Cyclacel to rebound in the second half:1. Bad news out of the way. Selciclib failed in the APPRAISE trial and will no longer weigh on the share price.2. Major up/down catalysts approaching. The SEAMLESS phase III trial of sapacitabine in elderly AML began in January and will determine the future of the company, or lack thereof. Topline data for sapacitabine in NSCLC is also expected later this year.3. Financially stable through catalysts. About 35M in cash reserves after today's financing and a burn rate of about 5M/quarter.4. New 18 month low today.Cyclacel could certainly go lower since catalysts are still many months if not more than a year away. But I'll take my CAPS position here as this could become a GBMB play if it continues to drop below 1.
Bought 10000 shares today at 1.18 for the GBMB account.
Any new concern with this stock, or are we just seeing irrational dumping due to the delisting threat?
The burn rate now seems to be much higher than $5M / quarter.
Sold all shares today at 7.68 (interim 7:1 reverse split) for a $850 GBMB loss. Disappointing, but considering I was down more than $7000 at one point I'm pleased.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions